BIOASTER has entered into a collaboration agreement with Takeda to develop and validate new microbiome-based approaches in the context of Takeda’s clinical-stage assets for the treatment of gastrointestinal diseases.
This collaboration with Takeda is an important step for BIOASTER in demonstrating its ability to support the clinical development of promising therapies with innovative approaches based on flow cytometry, cell sorting and “culturomics” to better understand the mode of action of the drug.